INmune Bio (NASDAQ: INMB) is an immunology company
focused on developing treatments that harness the patient’s innate immune
system to fight disease, such as Alzheimer’s disease (“AD”). A recent article
discussing the company reads, “An association between inflammation and
Alzheimer’s disease has long been established. Until present, however, this
link and the way in which it could be used to offer reliable AD treatments have
both been overlooked. Numerous inflammatory markers are found in AD patients,
and several studies establish a link between chronic inflammation and the
development of AD. . . . XPro1595 works by targeting the microglial immune
cells of the brain. These cells are activated in many AD patients. They cause
neuroinflammation that kills nerve cells and promotes synaptic dysfunction.
Combined, these two effects lead to dementia in people with AD.”
To view the full article, visit http://ibn.fm/CQDlC
About INmune Bio Inc.
INmune Bio is a publicly traded, clinical-stage
biotechnology company developing therapies targeting the innate immune system
to fight disease. INmune Bio is developing three product platforms: two
products that reengineer the patient’s innate immune system’s response to
cancer and one product to treat neuroinflammation that is currently focused on
Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that
primes the patient’s NK cells to attack minimal residual disease, the remaining
cancer cells that are difficult to detect, which often cause relapse. INB03
inhibits myeloid derived suppressor cells (“MDSC”), which often cause
resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595
targets neuroinflammation, which causes microglial activation and neuronal cell
death. INmune Bio’s product platforms utilize a precision medicine approach for
the treatment of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. To learn more, please visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
